The Valley Desk

NCT03739814 · Interventional trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Overall registry status Recruiting

Phase 2

Conditions B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov